Compare IDEXX Laboratories, Inc. (IDXX) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Oklo Inc — how do they compare? IDEXX Laboratories, Inc. trades at $551.53 (market cap $44.48B), while Oklo Inc trades at $43.92 (market cap $7.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.2× Oklo Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| IDXX | OKLO | |
|---|---|---|
Market Cap | $44.48B | $7.22B |
Sector | Health | Technology |
52-Week High | $766.68 | $174.14 |
52-Week Low | $520.87 | $41.11 |
Enterprise Value | $45.38B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
OKLO trades at $41.51, down 42% year-to-date amid regulatory uncertainty and recent stock dilution. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but fundamentals remain weak with negative earnings and cash flow. Recent news highlights progress on nuclear projects but regulatory hurdles persist.
OKLO presents high-risk/high-reward potential with significant upside to analyst targets but faces execution risks and negative profitability. The stock's bearish technical signals contrast with bullish long-term nuclear energy thesis. Regulatory approvals and Meta partnership execution remain critical catalysts for valuation recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
